IQVIA Holdings Inc. $IQV Shares Sold by CenterBook Partners LP

CenterBook Partners LP lessened its stake in shares of IQVIA Holdings Inc. (NYSE:IQV) by 80.9% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 5,301 shares of the medical research company’s stock after selling 22,429 shares during the quarter. CenterBook Partners LP’s holdings in IQVIA were worth $1,195,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also modified their holdings of the company. Claret Asset Management Corp increased its stake in IQVIA by 1.1% in the third quarter. Claret Asset Management Corp now owns 4,527 shares of the medical research company’s stock valued at $860,000 after purchasing an additional 49 shares during the last quarter. Leonard Rickey Investment Advisors P.L.L.C. lifted its position in IQVIA by 3.3% during the fourth quarter. Leonard Rickey Investment Advisors P.L.L.C. now owns 1,814 shares of the medical research company’s stock valued at $409,000 after buying an additional 58 shares in the last quarter. Brookstone Capital Management boosted its position in IQVIA by 2.2% during the 4th quarter. Brookstone Capital Management now owns 2,931 shares of the medical research company’s stock worth $661,000 after purchasing an additional 63 shares during the period. Private Advisor Group LLC grew its stake in shares of IQVIA by 1.0% in the third quarter. Private Advisor Group LLC now owns 6,122 shares of the medical research company’s stock valued at $1,163,000 after buying an additional 63 shares in the last quarter. Finally, Keybank National Association OH raised its stake in shares of IQVIA by 0.7% during the fourth quarter. Keybank National Association OH now owns 9,103 shares of the medical research company’s stock valued at $2,052,000 after purchasing an additional 67 shares during the period. 89.62% of the stock is currently owned by hedge funds and other institutional investors.

IQVIA Stock Down 2.1%

IQV opened at $182.28 on Thursday. The stock’s 50 day moving average price is $173.18 and its 200 day moving average price is $194.08. The company has a debt-to-equity ratio of 2.20, a current ratio of 0.75 and a quick ratio of 0.75. The stock has a market cap of $30.42 billion, a P/E ratio of 22.59, a P/E/G ratio of 1.60 and a beta of 1.21. IQVIA Holdings Inc. has a 12 month low of $153.01 and a 12 month high of $247.04.

IQVIA (NYSE:IQV) last released its quarterly earnings results on Tuesday, May 5th. The medical research company reported $2.90 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.83 by $0.07. The company had revenue of $4.15 billion during the quarter, compared to analysts’ expectations of $4.10 billion. IQVIA had a return on equity of 30.50% and a net margin of 8.33%.The company’s revenue for the quarter was up 8.4% compared to the same quarter last year. During the same quarter in the prior year, the business posted $2.70 earnings per share. IQVIA has set its FY 2026 guidance at 12.650-12.950 EPS. As a group, research analysts predict that IQVIA Holdings Inc. will post 11.6 earnings per share for the current year.

IQVIA declared that its board has initiated a stock repurchase plan on Thursday, May 7th that authorizes the company to repurchase $2.00 billion in shares. This repurchase authorization authorizes the medical research company to repurchase up to 6.8% of its stock through open market purchases. Stock repurchase plans are usually a sign that the company’s board of directors believes its stock is undervalued.

Wall Street Analysts Forecast Growth

IQV has been the subject of a number of research analyst reports. Weiss Ratings lowered shares of IQVIA from a “hold (c)” rating to a “hold (c-)” rating in a research note on Monday, May 4th. HSBC set a $210.00 price target on shares of IQVIA in a research report on Wednesday, June 3rd. Mizuho set a $215.00 target price on shares of IQVIA in a report on Monday, February 23rd. Truist Financial decreased their target price on IQVIA from $290.00 to $245.00 and set a “buy” rating for the company in a research note on Thursday, February 19th. Finally, TD Cowen upgraded IQVIA from a “hold” rating to a “buy” rating and increased their price target for the stock from $174.00 to $213.00 in a research report on Monday, March 9th. Two equities research analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating and two have issued a Hold rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Buy” and an average target price of $224.13.

IQVIA Profile

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.